The legal challenge centers on the period between March 9 and June 24, 2026, during which ARS management reportedly signaled that a July 1 coverage deadline for its epinephrine nasal spray, neffy, was well within reach. Investors claim that analyst expectations and subsequent share prices were built upon these assurances, ignoring the reality that CVS Caremark—the only major pharmacy benefit manager without unrestricted access—remained a holdout. When the July 1 cycle passed without the anticipated agreement, the stock price dropped from $10.54 to $8.02, wiping out significant shareholder value.

Analysts at William Blair described the delay as a negative shock, noting that the timing effectively sidelined neffy for the peak back-to-school season. The complaint, filed in the U.S. District Court for the Southern District of California, asserts that the company’s public disclosures failed to account for the rigidity of the Caremark approval process. Joseph E. Levi of Levi & Korsinsky, the firm representing the class, argues that the market correction was a direct consequence of information gaps regarding the company’s commercial strategy. Investors seeking to participate as lead plaintiffs in the action have until October 5, 2026, to submit their claims.